This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Dendreon: No-Drama Quarter Seen As Big Win

BRIDGEWATER, NJ ( TheStreet) -- Dendreon (DNDN) reported Provenge sales of $78 million for the September quarter, down sequentially and short of Street expectations again, yet the stock soared higher at Friday's open because some investors see a light emerging from the end of a long, dark tunnel.

As I mentioned in my preview, the best thing Dendreon had going for it coming into today's third-quarter earnings was ultra-low expectations. Investors were so accustomed to Dendreon blowing itself up four times a year that Friday's no-drama report was a giant upside surprise.

Dendreon shares jumped 24% to $4.75 in early Friday trading. Of course, some perspective is in order. Coming into today, Dendreon shares hadn't traded this cheap since before Provenge's phase III study results were announced three years ago.

Provenge sales of $78 million in the quarter were up 28% year over year but down 2.5% sequentially. Provenge quarterly sales must reach $100 million for Dendreon to be cash flow positive on an operating basis. Provenge sales are actually moving in the wrong direction but 14% quarter-over-quarter growth among community urologists -- the drug's target audience -- suggests a turnaround is possible.

"The community setting is where we will see most of our Provenge growth going forward," said Dendreon CFO Greg Schiffman on Friday's conference call.

Dendreon certainly needs community urologists to use more Provenge because demand elsewhere lags. Performance with community oncologists was flat quarter over quarter (although that's an improvement over an 8% decline in the second quarter.)

More troubling was the 25% decline in Provenge use by academic oncologists. Dendreon blamed the fall on competition from clinical trials of other experimental drugs. Perhaps, but it also lends weight to the argument that academic oncologists have never truly embraced Provenge because they simply don't believe the survival data upon which the drug was approved.

Dendreon executives insisted that Johnson & Johnson's (JNJ - Get Report) prostate cancer drug Zytiga has not significantly impacted Provenge use to date. However, on its own call last week, J&J estimated that Zytiga market share in the pre-chemo setting -- where it's not yet approved -- was already 30%. The FDA is expected to make an approval decision by Dec. 14 on Zytiga in the pre-chemo prostate cancer setting.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
DNDN $0.06 -6.02%
JNJ $100.34 0.00%
MDVN $132.00 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs